MedTrace Logo

eGPA and Local Inflammation Within the Ear, Nose and Throat Area

NCT06298448 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 150

Last updated 2024-03-07

No results posted yet for this study

Summary

Rationale: Eosinophilic Granulomatosis with Polyangiitis (eGPA), eosinophilic asthma and chronic rhinosinusitis with nasal polyps (CRSwNP) are airway diseases where eosinophils and interleukine-5 are involved in the pathogenesis. eGPA differs from the other diseases with respect to involvement of other organs. The investigators hypothesize that nasal microbiome dysbiosis with a central augmenting role for S. Aureus plays an important role in disease expression. The investigators expect that anti-interleukin-5 treatment with mepolizumab restores the changes of the nasal microbiome and immune responses to a healthy control phenotype. To study this, the nasal microbiome, the local and systemic immune response and the effect of mepolizumab treatment will be assessed.

Conditions

  • EGPA - Eosinophilic Granulomatosis With Polyangiitis

Interventions

DIAGNOSTIC_TEST

laboratory experiments before and after mepolizumab treatment

Patients that start with mepolizumab treatment on the basis of the clinical disease course will be measured prior and after start of mepolizumab to evaluate the effects this medication has on various immunological parameters and microbiome

Sponsors & Collaborators

  • GlaxoSmithKline

    collaborator INDUSTRY

  • University Medical Center Groningen

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-02-14
Primary Completion
2027-12-31
Completion
2028-12-31

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06298448 on ClinicalTrials.gov